[go: up one dir, main page]

AR073099A2 - Analogos de ghrelina - Google Patents

Analogos de ghrelina

Info

Publication number
AR073099A2
AR073099A2 ARP090103204A ARP090103204A AR073099A2 AR 073099 A2 AR073099 A2 AR 073099A2 AR P090103204 A ARP090103204 A AR P090103204A AR P090103204 A ARP090103204 A AR P090103204A AR 073099 A2 AR073099 A2 AR 073099A2
Authority
AR
Argentina
Prior art keywords
aib
acc
deleted
dap
dab
Prior art date
Application number
ARP090103204A
Other languages
English (en)
Original Assignee
Sod Conseils Rech Applic
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sod Conseils Rech Applic filed Critical Sod Conseils Rech Applic
Publication of AR073099A2 publication Critical patent/AR073099A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A61P5/04—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin for decreasing, blocking or antagonising the activity of the hypothalamic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/60—Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Gynecology & Obstetrics (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)

Abstract

Análogos de GHrelina, junto con usos terapéuticos y no terapéuticos de los mismos. Reivindicacion 1: Un compuesto conforme a la formula: (R2R3)-A1-A2-A3-A4-A5-A6-A7-A8-A9-A10-A11-A12-A13-A14-A15-A16-A17-A18-A19-A20-A21-A22-A23-A24-A25-A26-A27-A28-R1 o una sal farmacéuticamente aceptable del mismo, en donde: A1 es Gly, Aib, Ala, b-Ala, o Acc; A2 es Ser, Aib, Act, Ala, Acc, Abu, Act, Ava, Thr, o Val; A3 es Ser, Ser(C(O)-R4), Asp(O-R8), Asp(NH-R9), Cys(S-R14), Dap(S(O)2-R10), Dab(S(O)2-R11), Glu(O-R6), Glu(NH-R7), Thr, Thr(C(O)-R5), o HN-CH((CH2)n-N(R12R13))-C(O); A4 es Phe, Acc, Aic, Cha, 2Fua, 1Nal, 2Nal, 2Pal, 4Pal, hPhe, (X1,X2,X3,X4,X5)Phe, Taz, 2Thi, 3Thi, Trp, o Tyr; A5 es Leu, Abu, Acc, Aib, Ala, Cha, Ile, hLeu, Nle, Nva, Phe, Tle, o Val; A6 es Ser, Abu, Acc, Act, Aib, Ala, Gly, Thr, o Val; A7 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A8 es Glu, Acc, Aib, Arg, Asn, Asp, Dap, Gln, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A9 es His, Apc, Aib, Acc, 2Fua, 2Pal, 3pal, 4Pal, Taz, 2Thi, 3Thi, (X1,X2,X3,X4,X5-)Phe o eliminado; A10 es Gln, Acc, Aib, ASn, ASp, Glu, o eliminado; A11 es Arg, Apc, hArg, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A12 es Val, Abu, Acc, Aib, Ala, Cha, Nva, Gly, Ile, Leu, Nle, Tle, Cha, o eliminado; A13 es Gln, Acc, Aib, Asn, Asp, Glu, o eliminado; A14 es Gln, Acc, Aib, Asn, Asp, Glu, o eliminado; A15 es Arg, hArg, Acc, Aib, Apc, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A16 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A17 es Glu, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A18 es Ser, Abu, Acc, Act, Aib, Ala, Thr, Val, o eliminado; A19 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A20 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A21 es Pro, Dhp, Dmt, Inc, 3Hyp, 4Hyp, Ktp, Oic, Pip, Thz, Tic, o eliminado; A22 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A23 es Abu, Acc, Act, Aib, Ala, Apc, Gly, Nva, Val, o eliminado; A24 es Lys, Acc, Aib, Apc, Arg, hArg, Dab, Dap, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; A25 es Leu, Abu, Acc, Aib, Ala, Cha, Ile, hLeu, Nle, Nva, Phe, Tle, Val, o eliminado; A26 es Gln, Aib, Asn, Asp, Glu, o eliminado; A27 es Pro, Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz, Tic, o eliminado; A28 es Acc, Aib, Apc, Arg, hArg, Dab, Dap, Lys, Orn, HN-CH((CH2)n-N(R12R13))-C(O), o eliminado; R1 es -OH, -NH2, -alcoxi C1-30, o NH-X6-CH2-Z0, en donde X6 es un alquilo C1-12, alquenilo C2-12, y Z0 es -H, -OH, -CO2H o -C(O)-NH2; R2 y R3 son, cada uno en forma independiente para cada aparicion, H, alquilo C1-20 o acilo C1-20; R4, R5, R6, R7, R8, R9, R10, R11 y R14 son, cada uno en forma independiente para cada aparicion, alquilo C1-40, alquenilo (C2-40, alquilo C1-40 sustituido, alquenilo C2-40 sustituido, alquilarilo, alquilarilo sustituido, arilo o arilo sustituido; R12 y R13 son, cada uno en forma independiente para cada aparicion, H, alquilo C1-40, acilo C1-40, alquilsulfonilo C1-30, o -C(NH)-NH2, en donde cuando R12 es acilo C1-40, alquilsulfonilo C1-30, o -C(NH)-NH2, entonces R13 es H o alquilo C1-40; n es, en forma independientemente para cada aparicion, 1, 2, 3, 4, o 5; X1, X2, X3, X4 y X5 son, cada uno en forma independiente para cada aparicion, H, F, Cl, Br, I, alquilo C1-10, alquilo C1-10 sustituido, arilo, arilo sustituido, OH, NH2, NO2, o CN; siempre que el péptido contenga por lo menos un aminoácido seleccionado entre los grupos que consisten en: A2 es Aib, Acc, o Act; A3 es Dap(S(O)2-R10), Dab(S(O)2-R11), Glu(NH-Hexil), o Cys(S-Decil); A5 es Abu, Acc, Aib, Ala, Cha, Ile, hLeu, Nle, Nva, Phe, Tle, o Val; A6 es Abu, Acc, Act, Aib, Ala, Gly, Thr o Val; A7 es Dhp, Dmt, 3Hyp, 4Hyp, Inc, Ktp, Oic, Pip, Thz o Tic; A8 es Acc, Aib, Arg, Asn, Asp, Dab, Dap, Gln, Lys, Orn, o HN-CH((CH2)n-N(R12R13))-C(O); A9 es Aib, Acc, Apc, 2Fua, 2Pal, 3Pal, 4Pal, Taz, 2Thi, 3Thi, o (X1,X2,X3,X4,X5-)Phe; y A10 es Acc, Aib, Asn, Asp, o Glu; y además, siempre que el péptido no sea (Lys8)hGHrelina(1-8)-NH2 o (Arg8)hGHrelina(1-8)-NH2.
ARP090103204A 2002-07-23 2009-08-20 Analogos de ghrelina AR073099A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US39783402P 2002-07-23 2002-07-23
US42748802P 2002-11-19 2002-11-19

Publications (1)

Publication Number Publication Date
AR073099A2 true AR073099A2 (es) 2010-10-13

Family

ID=34278194

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP030102647A AR040955A1 (es) 2002-07-23 2003-07-23 Analogos de ghrelina
ARP090103204A AR073099A2 (es) 2002-07-23 2009-08-20 Analogos de ghrelina

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP030102647A AR040955A1 (es) 2002-07-23 2003-07-23 Analogos de ghrelina

Country Status (18)

Country Link
US (3) US7589058B2 (es)
EP (2) EP2258381A3 (es)
JP (2) JP2006515271A (es)
KR (1) KR101065471B1 (es)
AR (2) AR040955A1 (es)
AT (1) ATE496940T1 (es)
AU (1) AU2003254119B2 (es)
BR (1) BR0312871A (es)
CA (1) CA2491946C (es)
DE (1) DE60335913D1 (es)
IL (1) IL166170A (es)
MX (1) MXPA05000908A (es)
NO (1) NO334857B1 (es)
PL (1) PL212106B1 (es)
PT (1) PT1578778E (es)
RU (3) RU2373220C2 (es)
TW (1) TWI325003B (es)
WO (1) WO2004009616A2 (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006515271A (ja) 2002-07-23 2006-05-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス グレリン類似体
CA2566703A1 (en) * 2004-05-11 2005-11-24 Vishwa Deep Dixit Methods of inhibiting proinflammatory cytokine expression using ghrelin
WO2007038678A2 (en) 2005-09-28 2007-04-05 Societe De Conseils De Recherches Et D'applications Scientifiques S.A.S. Analogs of ghrelin
RU2427587C2 (ru) * 2005-09-28 2011-08-27 Ипсен Фарма С.А.С. Аналоги грелина
RU2420305C2 (ru) * 2005-09-29 2011-06-10 Ипсен Фарма С.А.С. Композиции и способы стимуляции двигательной функции желудочно-кишечного тракта
WO2007092023A1 (en) * 2006-02-11 2007-08-16 Boston Biomedical Research Institute Compositions and methods for binding or inactivating ghrelin
US20100227806A1 (en) 2006-03-10 2010-09-09 Tulipano Giovanni Use Of A Ghrelin Agonist To Improve Catabolic Effects Of Glucocorticoid Treatment
NZ571183A (en) * 2006-03-13 2010-09-30 Liat Mintz Use of ghrelin splice variant for treating cachexia and/or anorexia and/or anorexia-cachexia and/or malnutrition and/or lipodystrophy and/or muscle wasting and/or appetite stimulation
US8299022B2 (en) * 2006-09-27 2012-10-30 Ipsen Pharma S.A.S. Analogs of ghrelin substituted at the N-terminal
WO2008067831A2 (en) * 2006-12-05 2008-06-12 Charite Universitätsmedizin - Berlin Use of ghrelin, an analogue thereof or a pharmaceutically acceptable salt thereof
TW200916113A (en) * 2007-08-08 2009-04-16 Sod Conseils Rech Applic Method for inhibiting inflammation and pro-inflammatory cytokine/chemokine expression using a ghrelin analogue
US9724381B2 (en) 2009-05-12 2017-08-08 The Administrators Of The Tulane Educational Fund Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
US8883721B2 (en) * 2009-05-12 2014-11-11 Mcgill University Methods of inhibiting the ghrelin/growth hormone secretatogue receptor pathway and uses thereof
CA2778990A1 (en) 2009-10-30 2011-05-05 Tranzyme Pharma, Inc. Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same
EP2582715B1 (en) * 2010-06-16 2018-11-28 The Administrators of the Tulane Educational Fund Growth hormone secretatogue receptor antagonists and uses thereof
JP5560248B2 (ja) * 2011-09-07 2014-07-23 花王株式会社 ジペプチド誘導体及びその製造方法
WO2013113916A2 (en) * 2012-02-03 2013-08-08 Zealand Pharma A/S Ghrelin analogues
DK2849567T3 (da) 2012-05-17 2022-06-20 Extend Biosciences Inc Bærestoffer til forbedret lægemiddeladministration
US9119832B2 (en) 2014-02-05 2015-09-01 The Regents Of The University Of California Methods of treating mild brain injury
WO2016065052A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Insulin vitamin d conjugates
US9789197B2 (en) 2014-10-22 2017-10-17 Extend Biosciences, Inc. RNAi vitamin D conjugates
WO2016065042A1 (en) 2014-10-22 2016-04-28 Extend Biosciences, Inc. Therapeutic vitamin d conjugates
WO2017075535A1 (en) 2015-10-28 2017-05-04 Oxeia Biopharmaceuticals, Inc. Methods of treating neurodegenerative conditions
CN108029863B (zh) * 2018-01-19 2021-07-27 广州英赛特生物技术有限公司 丁酰甘氨酸及其衍生物在制备动物饲料添加剂中的应用
EP4593867A2 (en) 2022-09-30 2025-08-06 Extend Biosciences, Inc. Long-acting parathyroid hormone

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8821785D0 (en) * 1988-09-16 1988-10-19 Nycomed As Peptide compounds
US5264565A (en) 1991-01-22 1993-11-23 Affymax Technologies, N.V. Nucleic acid encoding the D2 /Ml chimeric receptor
EP0783521B8 (en) * 1994-09-27 2003-04-09 Ardana Bioscience Limited Polypeptide compounds containing d-2-alkyltryptophan capable of promoting the release of growth hormone
EP0783577B1 (en) 1995-07-26 2008-07-09 AstraZeneca AB Chimeric receptors and methods for identifying compounds active at metabotropic glutamate receptors and the use of such compounds in the treatment of neurological disorders and diseases
EP0876402B1 (en) 1995-12-13 2004-10-13 Merck & Co., Inc. Growth hormone secretagogue receptor family
PL208751B1 (pl) * 1998-12-07 2011-06-30 Sod Conseils Rech Applic Związki stanowiące analogi GLP-1, kompozycje zawierające takie związki oraz zastosowanie takich związków
ES2288151T3 (es) * 1999-07-23 2008-01-01 Kenji Kangawa Nuevos peptidos.
US6967237B2 (en) * 2000-05-30 2005-11-22 Merck & Co., Inc. Ghrelin analogs
KR20030033002A (ko) * 2000-07-24 2003-04-26 아다나 바이오싸이언스 리미티드 그렐린 길항제
ATE512216T1 (de) * 2001-04-10 2011-06-15 Agensys Inc Nukleinsäure und dieser entsprechendes, 184p1e2 genanntes, für die behandlung und den nachweis von krebs geeignetes protein
JP2006515271A (ja) 2002-07-23 2006-05-25 ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス グレリン類似体

Also Published As

Publication number Publication date
RU2315059C2 (ru) 2008-01-20
JP2006515271A (ja) 2006-05-25
IL166170A (en) 2011-01-31
US7589058B2 (en) 2009-09-15
BR0312871A (pt) 2007-07-10
US20140135260A1 (en) 2014-05-15
CA2491946A1 (en) 2004-01-29
PT1578778E (pt) 2011-03-07
CA2491946C (en) 2013-05-28
NO334857B1 (no) 2014-06-23
AR040955A1 (es) 2005-04-27
WO2004009616A3 (en) 2006-02-09
NO20050083L (no) 2005-03-23
US8633151B2 (en) 2014-01-21
DE60335913D1 (de) 2011-03-10
RU2005104841A (ru) 2005-09-10
JP2009161546A (ja) 2009-07-23
ATE496940T1 (de) 2011-02-15
EP1578778A2 (en) 2005-09-28
EP2258381A3 (en) 2011-11-02
EP1578778A4 (en) 2007-02-28
RU2009127162A (ru) 2011-01-20
TWI325003B (en) 2010-05-21
RU2007124275A (ru) 2009-01-10
KR101065471B1 (ko) 2011-09-16
US20050272648A1 (en) 2005-12-08
AU2003254119B2 (en) 2007-11-29
PL377075A1 (pl) 2006-01-23
US20100069299A1 (en) 2010-03-18
AU2003254119A1 (en) 2004-02-09
WO2004009616A2 (en) 2004-01-29
PL212106B1 (pl) 2012-08-31
RU2373220C2 (ru) 2009-11-20
EP2258381A2 (en) 2010-12-08
MXPA05000908A (es) 2005-07-22
US9133261B2 (en) 2015-09-15
TW200403253A (en) 2004-03-01
KR20050026503A (ko) 2005-03-15
EP1578778B1 (en) 2011-01-26
IL166170A0 (en) 2006-01-15

Similar Documents

Publication Publication Date Title
AR073099A2 (es) Analogos de ghrelina
AR061780A1 (es) Analogos de ghrelina sustituidos en el extremo n- terminal
ES2877349T3 (es) Ligandos de los receptores de la melanocortina
JP4346115B2 (ja) Ｌｈ−ｒｈペプチド類似体、その使用及びそれを含有する薬用組成物
AR066175A1 (es) Ligandos del receptor de melanocortina de peptidos ciclicos
AR043688A1 (es) Analogos del peptido yy
KR960703015A (ko) 후천성 면역결핍증 치료용 약물의 제조시 노나- 및 데카펩타이드의 용도(Use of nona-and decapeptides in the preparation of a durg for the treatment of AIDS)
RU2008104802A (ru) Лиганды рецепторов меланокортинов
CA2097192A1 (en) Bombesin antagonists
KR930701483A (ko) Grf (쥐이알에프) 유사체 xi
KR910002900A (ko) 합성 펩티드 및 이를 함유하는 제약학적 조성물
AR049149A1 (es) Analogos antagonistas de gh-rh
RU96123269A (ru) Три-, тетра-, пента- и полипептиды и их терапевтическое применение в качестве антидепрессивного агента
AR076950A2 (es) Analogos del peptido 1-similar al glucagon uso de los mismos para la manufactura de un medicamento y composiciones farmaceuticas que los contienen
KR920700225A (ko) Grf 유사체 viia
EP0937101B1 (en) Conformationally constrained lh-rh analogues, their uses and pharmaceutical compositions containing them
HU190949B (en) Process for producing peptides antagonistic with hormones for releasing gonadotropine
ATE92078T1 (de) Pharmakologisch aktive peptide.
EP1818061A1 (en) Use of ghrelin for stimulating hair growth
ES2361818T3 (es) Análogos de la grelina.
MXPA99004512A (es) Analogos lh-rh conformacionalmente restringidos,sus usos y composiciones farmaceuticas que los contiene
TH35998A (th) Lh-rh เป็ปไทด์ อะนาล็อก ประโยชน์ของสิ่งเหล่านั้นและองค์ประกอบทางเภสัชกรรมซึ่งประกอบด้วยสิ่งเหล่านั้น
HK1116687A (en) Composition for use in treating gastrointestinal dysmotility

Legal Events

Date Code Title Description
FA Abandonment or withdrawal